Drug Trial Radar · NCT04844840
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
Last checked: Nov 19, 2026Latest source record: Mar 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Apr 29, 2021
Primary completion
May 17, 2023
Study completion May 17, 2023
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2, randomized, double-blind, multiple arm, controlled study to evaluate safety \& efficacy of various doses of STP705 in reducing post Keloidectomy keloid recurrence.
Conditions
- Keloid
Interventions
STP705Drug
STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively
PlaceboOther
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of RecurrenceTime frame: 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigate MD
Scottsdale, Arizona
Center for Clinical and Cosmetic Research
Aventura, Florida
Schweiger Dermatology
Hackensack, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.